The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index; 1 of the 6 sources its claims cite were checked for support.
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Open accessAbstract
The global supply of COVID-19 vaccines remains limited. An understanding of the immune response that is predictive of protection could facilitate rapid licensure of new vaccines. Data from a randomized efficacy trial of the ChAdOx1 nCoV-19 (AZD1222) vaccine in the United Kingdom was analyzed to determine the antibody levels associated with protection against SARS-CoV-2. Binding and neutralizing antibodies at 28 days after the second dose were measured in infected and noninfected vaccine recipients. Higher levels of all immune markers were correlated with a reduced risk of symptomatic infection. A vaccine efficacy of 80% against symptomatic infection with majority Alpha (B.1.1.7) variant of SARS-CoV-2 was achieved with 264 (95% CI: 108, 806) binding antibody units (BAU)/ml: and 506 (95% CI: 135, not computed (beyond data range) (NC)) BAU/ml for anti-spike and anti-RBD antibodies, and 26 (95% CI: NC, NC) international unit (IU)/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF 50) for pseudovirus and live-virus neutralization, respectively. Immune markers were not correlated with asymptomatic infections at the 5% significance level. These data can be used to bridge to new populations using validated assays, and allow extrapolation of efficacy estimates to new COVID-19 vaccines.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In the UK COV002 trial, higher anti-spike IgG, anti-RBD IgG, pseudovirus neutralizing, and live-virus neutralizing antibody levels at 28 days after a second ChAdOx1 nCoV-19 dose were associated with lower risk of symptomatic COVID-19, but not asymptomatic infection. Antibody values corresponding to 80% vaccine efficacy against primary symptomatic COVID-19 were 264 BAU/ml for anti-spike IgG, 506 BAU/ml for anti-RBD IgG, 26 IU/ml for pseudovirus neutralization, and 247 NF50 for live-virus neutralization.
Key findings
- Among 4,372 participants in the correlates population, there were 174 breakthrough NAAT+ SARS-CoV-2 infections; correlates analysis included 171 cases and 1,404 noncases with at least one assay readout. Risk of symptomatic COVID-19 decreased with increasing anti-spike IgG (P = 0.003), anti-RBD IgG (P = 0.018), pseudovirus neutralization titer (P = 0.005), and live-virus neutralization titer (P < 0.001).
- The antibody level associated with 80% VE against primary symptomatic COVID-19 was 40,923 AU/ml anti-spike IgG, equivalent to 264 BAU/ml (95% CI: 108, 806); 506 BAU/ml anti-RBD IgG (95% CI: 135, NC); 26 IU/ml pseudovirus neutralization (95% CI: NC, NC); and 247 NF50 live-virus neutralization (95% CI: 101, NC).
- No significant associations were found between any assay and protection against asymptomatic infection, including in sensitivity analysis restricting to high viral load (all P > 0.05).
- For symptomatic cases with shortness of breath, 80% VE was achieved at lower immune marker levels than for symptomatic cases in general; no significant associations were observed for symptomatic cases without shortness of breath (all P > 0.05).
Methods
- Data came from COV002, a phase 2/3 randomized single-blind vaccine efficacy trial across 19 UK sites; participants were randomized to ChAdOx1 nCoV-19 or MenACWY control. The correlates population included baseline SARS-CoV-2 N-protein-seronegative participants with a PB28 visit within 14–42 days after the second dose and follow-up to at least 7 days after PB28; the correlates cohort comprised those with biomarker data.
- Immune markers measured at PB28 were anti-spike IgG, anti-RBD IgG, pseudovirus neutralization, and live-virus neutralization, converted to WHO international standard units. Outcomes were primary symptomatic COVID-19 (NAAT+ with at least one qualifying symptom) and asymptomatic infection (NAAT+ on weekly self-swab with no symptoms).
- Log-transformed immune markers were analyzed with generalized additive models for binary outcomes using cubic spline smooths, adjusted for baseline exposure risk and weighted by inverse probability weights for sample availability. Correlates of VE were derived by comparing predicted absolute risk with the MenACWY control population risk; 95% CIs used 10,000 bootstrap samples.
Limitations
- Stated: analyses were based on a mainly white UK population with cases mostly due to B.1.177 and B.1.1.7 variants, so modeled relationships may not apply where other variants dominate or different neutralization strains are used. Many analyses were conducted and P values are unadjusted for multiple comparisons. Results apply to two doses of ChAdOx1 nCoV-19 and may not apply to a single dose or other COVID-19 vaccines. Age profile was not explored due to few older adults; T cells and humoral–cellular interactions were not evaluated; mechanistic versus nonmechanistic correlates could not be determined. No vaccinated participants were hospitalized, so correlates against severe disease or hospitalization could not be assessed. Wide CIs around estimates should be noted, and no single threshold indicated sterilizing immunity.
- Evident from the text: the correlates relate to protection against mild disease, defined as NAAT+ with at least one symptom, during the subsequent 4- to 6-month period, and represent antibody levels at 28 days after a second dose rather than at the time of exposure.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
29 Own result · 18 Own method · 7 Own interpretation · 5 Not checked yet · 3 No basis given · 1 Partly supported · accuracy not yet measured
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The risk of symptomatic COVID-19 decreased with increasing levels of anti-spike IgG (P = 0.003), anti-RBD IgG (P = 0.018), pseudovirus neutralization titer (P = 0.005), and live-virus neutralization titer (P < 0.001)”
§ Correlates of protection > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The risk of symptomatic COVID-19 decreased with increasing levels of anti-spike IgG (P = 0.003)”
§ Correlates of protection > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The risk of symptomatic COVID-19 decreased with increasing levels of anti-spike IgG (P = 0.003), anti-RBD IgG (P = 0.018), pseudovirus neutralization titer (P = 0.005), and live-virus neutralization titer (P < 0.001)”
§ Correlates of protection > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The risk of symptomatic COVID-19 decreased with increasing levels of anti-spike IgG (P = 0.003), anti-RBD IgG (P = 0.018), pseudovirus neutralization titer (P = 0.005), and live-virus neutralization titer (P < 0.001)”
§ Correlates of protection > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Not all participants with results from the pseudovirus neutralization titer also have results from the anti-spike, anti-RBD, and live neutralizing antibody titers.”
§ Correlates of protection > Imputation of censored antibody values.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Non-normalized live-virus neutralization titers (ND 50 ) were less highly correlated with anti-spike IgG (r = 0.411) and pseudovirus neutralization titers (r = 0.305).”
§ Correlates of protection > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For anti-RBD IgG, 80% efficacy was achieved with median antibody level of 506 (95% CI: 135, not computed (NC)) BAU/ml”
§ Correlates of protection > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For pseudovirus and live-virus neutralizing antibody titers, values of 26 (95% CI: NC, NC) IU/ml and 247 (95% CI: 101, NC) normalized neutralization titers (NF 50 ), respectively, were associated with 80% VE against symptomatic infection”
§ Correlates of protection > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No values from these assays were associated with protection against asymptomatic infection (Supplementary Table 4)”
§ Correlates of protection > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“the results presented here show that there is no single threshold value for any of the assays investigated that was indicative of sterilizing immunity in our data.”
§ Correlates of protection > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 23
- It may state two separate claims as one. 10
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“When a bootstrap is required for missing data, Brand et al. found single imputation embedded inside a bootstrap showed better statistical properties than other methods 43 .”
§ Correlates of protection > Imputation of censored antibody values.
What the sources say
- Partly supportedcites [43] Brand, J., van Buuren, S., le Cessie, S. & van den Hout, W. Combining multiple imputation and bootstrap in the analysis of cost‐effectiveness trial data. Stat. Med. 38, 210–220 (2019). sourceExperimental — accuracy not yet measured
The Conclusion (§5) says single imputation embedded in the bootstrap percentile method had the best statistical properties, provided noise was added to reflect imputation uncertainty. The claim omits those conditions: the Discussion (§4) reports that single imputation embedded in the bootstrap-t method produced intervals that were too narrow and had considerable undercoverage. (LLM, conf=0.88)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In our baseline exposure model developed among the MenACWY control group, younger age and being a healthcare worker facing more than one patient with COVID-19 per day were associated with a higher risk of being NAAT+.”
§ Correlates of protection > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“VE against primary symptomatic COVID-19 as a function of immune markers measured at PB28.”
§ Correlates of protection > Reporting Summary.
plaincorrelationaln = 52- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Predicted absolute risk of primary symptomatic COVID-19 as a function of immune markers measured at PB28 by generalized additive regression.”
§ Correlates of protection > Reporting Summary.
plaincorrelationaln = 52- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Data were available for at least one of four assay readouts (anti-spike IgG, anti-receptor binding domain (RBD) IgG, pseudovirus neutralization assay, and live-virus neutralization) for 171 out of 174 (98.3%) cases and 1,404 out of 4,195 (33.5%) noncases.”
§ Correlates of protection > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“People in the case group were younger, with 84.2% being aged 18-55 years, compared with 71.6% of the noncase group”
§ Correlates of protection > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and were more likely to be healthcare workers (62.0% were healthcare workers compared with 57.5% of the noncase group, Table 1).”
§ Correlates of protection > Results
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Relative risk of primary symptomatic COVID-19 among vaccine recipients compared with MenACWY control arm participants as a function of immune markers measured at PB28.”
§ Correlates of protection > Reporting Summary.
plaincorrelationaln = 52- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Relative risk of asymptomatic SARS-CoV-2 infection among vaccine recipients compared with the MenACWY control arm participants as a function of immune markers measured at PB28.”
§ Correlates of protection > Reporting Summary.
plaincorrelationaln = 91- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“To account for potential of misclassification in asymptomatic infections, a sensitivity analysis was conducted excluding cases with lower viral loads (defined as those for whom all returned PCR positive tests had a CT value ≥ 30), as these are potential false positives.”
§ Correlates of protection > Sensitivity analyses. Viral load.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These observations indicate that the reduced neutralizing capacity against B.1.351and other variants of concern, might drive reduced protection against initial infection, and perhaps transmission, but protection against severe disease is maintained.”
§ Correlates of protection > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Sensitivity analysis showing absolute and relative risk primary symptomatic SARS-CoV-2 infection with 3 or more COVID-19 symptoms as a function of immune markers measured at day 28 post-second dose.”
§ Correlates of protection > Reporting Summary.
plaincorrelationaln = 32- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We performed a sensitivity analysis to account for the potential bias caused by imputing LLOQ / 2.”
§ Correlates of protection > Imputation of censored antibody values.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Correlates may also vary according to age profile, but this was not explored in our study due to the small number of older adults recruited.”
§ Correlates of protection > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Sensitivity analysis showing absolute and relative risk of asymptomatic SARS-CoV-2 infection as a function of immune markers measured at 28 days post second dose excluding cases with low viral load (Ct ≥ 30).”
§ Correlates of protection > Reporting Summary.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Sensitivity analysis showing absolute and relative risk of primary symptomatic SARS-CoV-2 infection in participants with no symptoms of shortness of breath as a function of immune markers measured at day 28 post-second dose.”
§ Correlates of protection > Reporting Summary.
plaincorrelationaln = 24- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Sensitivity analysis showing absolute and relative risk of primary symptomatic SARS-CoV-2 infection in participants with symptoms of shortness of breath as a function of immune markers measured at day 28 post-second dose.”
§ Correlates of protection > Reporting Summary.
plaincorrelationaln = 28- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A trial of a new vaccine that works through similar immune mechanisms and which produces antibody responses that are above the correlate values reported here in at least 50% of participants (that is, it has a similar or higher median), might be expected to have similar efficacy against the clinical endpoints used in our UK trial, and higher efficacy against more severe endpoints.”
§ Correlates of protection > Discussion
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: No study to date has defined a correlate of protection against SARS-CoV-2 infection or disease that can be used by regulators and vaccine developers.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Instead, the probability of infection decreases on average with higher immune responses, but substantial variation exists between individuals.”
§ Correlates of protection > Discussion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“We then estimated the CoR by GAM, adjusting for the baseline risk exposure and weighting by inverse probability weights.”
§ Correlates of protection > Bootstrap.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Similarly, ChAdOx1 nCoV-19-vaccinated hamsters, with low neutralizing titers against B.1.351,were fully protected against LRTI following challenge with B.1.351,despite no evidence of protection against shedding of virus from the upper airway 29 .”
§ Correlates of protection > Discussion
What the sources say
- Not checked yetcites [29] Fischer, R. J., et al. ChAdOx1 nCoV-19 (AZD1222) protects hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 disease. Nature Comm. (in the press).
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The logit-transformed predicted baseline exposure risk was included as a linear covariate in the GAM model.”
§ Correlates of protection > Correlates or risk.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
- Rests on an assumption: Baseline exposure risk predicted from the MenACWY control population is applicable to the ChAdOx1 nCoV-19 correlates cohort.
In the paper
“Protection against upper respiratory tract or asymptomatic infections may be more closely associated with the presence of secretory IgA on the mucosal surface which was not measured in this study 30 .”
§ Correlates of protection > Discussion
What the sources say
- Not checked yetcites [30] Wang, Z. et al. Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci. Transl. Med. 13, eabf1555 (2021). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Samples were tested blinded to case status.”
§ Correlates of protection > Immune markers and time points.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“It has previously been shown that protection against lower respiratory tract infection (LRTI) may be easier to achieve than against upper respiratory tract infection (URTI), as challenge studies in rhesus macaques have shown stronger correlation between neutralizing titers and the level of subgenomic messenger RNA in bronchoalveolar lavage samples than in nasal swab samples 28 .”
§ Correlates of protection > Discussion
What the sources say
- Not checked yetcites [28] van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586, 578–582 (2020). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“These analyses are based on cases of COVID-19 detected in a mainly white population in the United Kingdom, which were mostly due to B.1.177and B.1.1.7 variants.”
§ Correlates of protection > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The data included in this analysis comes from participants enrolled in COV002 (registration NCT04400838), a phase 2/3 randomized single-blind vaccine efficacy trial conducted across 19 sites in the United Kingdom.”
§ Correlates of protection > Study description.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For each bootstrap sample, we calculated the inverse probability weights to account for sampling bias.”
§ Correlates of protection > Bootstrap.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All endpoints were evaluated by a blinded independent clinical review committee.”
§ Correlates of protection > Study description.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data can be used to extrapolate efficacy estimates for new vaccines that use similar immune mechanisms and where efficacy data is unavailable.”
§ Correlates of protection > Discussion
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: fails — It may be too vague to check against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may be too vague to check against evidence.
- Rests on an assumption: No study to date has defined a correlate of protection against SARS-CoV-2 infection or disease that can be used by regulators and vaccine developers.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, these analyses have been conducted on samples taken after two doses of ChAdOx1 nCoV-19 and might not apply to protection afforded by a single dose of the same vaccine or other COVID-19 vaccines.”
§ Correlates of protection > Discussion
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The authors state this as an assumption.
The mechanism of missingness for samples that were not tested is missing at random.
“We assume the mechanism of missingness for samples that were not tested to be missing at random 39 .”
The paper relies on this without support.
No study to date has defined a correlate of protection against SARS-CoV-2 infection or disease that can be used by regulators and vaccine developers.
“Nevertheless, no study to date has defined a correlate of protection against SARS-CoV-2 infection or disease that can be used by regulators and vaccine developers.”
The paper relies on this without support.
Baseline exposure risk predicted from the MenACWY control population is applicable to the ChAdOx1 nCoV-19 correlates cohort.
“The linear predictor from the risk model developed using the MenACWY control population was used to predict the baseline risk of exposure in the ChAdOx1 nCoV-19 correlates cohort.”
The authors state this as an assumption.
The confidence ellipses for correlations assume a t-distribution.
“95% confidence ellipses assuming a t-distribution are shown for each outcome (primary symptomatic cases, asymptomatic cases and negative controls).”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Neutralizing antibody responses are also believed to be critical for protection against COVID-19 by BNT vaccination”
From The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic (2022) · cites this paper as Feng et al., 2021
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Wood, S. N. (2010) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/j.1467-9868.2010.00749.x · Cited by 7,538
Sterne, J. A. C., White, I. R., Carlin, J. B., Spratt, M., Royston, P., Kenward, M. G., Wood, A. M., & Carpenter, J. R. (2009) · BMJ · doi:10.1136/bmj.b2393 · Cited by 7,299
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Self-citationKhoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · Nature Medicine · doi:10.1038/s41591-021-01377-8 · Cited by 3,742
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Self-citationMulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., et al. (2020) · doi:10.1101/2020.06.30.20142570 · Cited by 1,569
Haas, E. J., Angulo, F. J., McLaughlin, J. M., Anis, E., Singer, S. R., Khan, F., Brooks, N., Smaja, M., Mircus, G., Pan, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00947-8 · Cited by 1,564
Lopez Bernal, J., Andrews, N., Gower, C., Robertson, C., Stowe, J., Tessier, E., Simmons, R., Cottrell, S., Roberts, R., O’Doherty, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1088 · Cited by 1,389
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324
Self-citation
Research works printed but not linked: 2
- Kemp, A. AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis. https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-us-vaccine-trial-met-primary-endpoint.html (2021).
- Box, G. E. & Tiao, G. C. Bayesian Inference in Statistical Analysis (John Wiley & Sons, 2011).
Cited by
Sorted by citations
Items 701–800 of 1,000
Thimmiraju, S. R., Villar, M. J., Kimata, J. T., Strych, U., Bottazzi, M. E., Hotez, P. J., & Pollet, J. B. K. (2024) · Viruses · doi:10.3390/v16091492 · Cited by 4
Hwang, Y. H., Min, D., & Park, W. B. (2025) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2025.2473795 · Cited by 4
Viral Dynamic Models During COVID ‐19: Are We Ready for the Next Pandemic?
Marc, A., Schiffer, J. T., Mentré, F., Perelson, A. S., & Guedj, J. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70055 · Cited by 4
Ponce, L. J., Wang, Y., Singh, A., Chua, H. C., Chen, M., Hor, P. X., Loh, C. Y., Poh, X. Y., Rao, S., Chia, P. Y., et al. (2025) · Journal of Medical Virology · doi:10.1002/jmv.70521 · Cited by 4
Self-citationPurcell, R. A., Koutsakos, M., Kedzierski, Ł., Allen, L. F., Williams, O., Wang, J.-W. D., Cavic, G., Wheatley, A. K., Lee, W. S., Wines, B. D., et al. (2025) · npj Vaccines · doi:10.1038/s41541-025-01268-w · Cited by 5
Self-citationSystemic and mucosal immune signatures of protection against SARS-CoV-2 transmission in humans
Rojo-Fernandez, A., Aslam, S., Alam, F., Escalera, A., Villamandos, V., Caton, B., Megías, G., Gonzalez, A., Buzón, L., Ayllón, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102505 · Cited by 5
El-Shazly, A. A. A., Abd‐Elmawla, M. A., Abulfadl, Y. S., Omar, N. N., & Rizk, S. M. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109655 · Cited by 4
Grunau, B. E., Golding, L., Prusinkiewicz, M. A., Asamoah-Boaheng, M., Armour, R., Marquez, A. C., Jassem, A. N., Barakauskas, V., O’Brien, S. F., Drews, S. J., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02702-21 · Cited by 4
Girl, P., Mantel, S., von Buttlar, H., Wölfel, R., & Müller, K. (2022) · Viruses · doi:10.3390/v14030577 · Cited by 4
Rapid SARS-CoV-2 Seroprevalence Survey in Central and Western Divisions of Fiji, 2021
Curtis, S. J., Shah, A. W., Ratu, A., Wilson, D., Hill, P. C., Hulcome, P., Gaylard, C., Faktaufon, D., Cabemaiwai, T., Rabukawaqa, I., et al. (2023) · Emerging infectious diseases · doi:10.3201/eid2901.221514 · Cited by 4
Holtkamp, C., Schöler, L., Anastasiou, O. E., Brune, B., Fessmann, K., Elsner, C., Möhlendick, B., Čiučiulkaitė, I., Dudda, M., Trilling, M., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12746 · Cited by 4
Boosting maternal and neonatal anti–SARS-CoV-2 humoral immunity using a third mRNA vaccine dose
Cahen‐Peretz, A., Tsaitlin-Mor, L., Kam, H. A., Frenkel, R., Kabessa, M., Cohen, S. M., Lipschuetz, M., Oiknine‐Djian, E., Lianski, S., Goldman‐Wohl, D., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.158646 · Cited by 5
Buscot, M., Crémoni, M., Graça, D., Brglez, V., Courjon, J., Allouche, J., Teisseyre, M., Boyer, L., Barrière, J., Chamorey, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145652 · Cited by 5
Gonzales, M. L. A. M., Dans, L. F., Tan‐Lim, C. S. C., Uy, E. J. B., Paz, E. C.-D., Sulit, M. V. V., Alejandria, M. M., Lansang, M. A., Dans, A. L., Dator, M. A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1190093 · Cited by 4
Dai, Y.-C., Lin, Y.-C., Ching, L. L., Tsai, J., Ishikawa, K. M., Tsai, W.-Y., Chen, J. J., Nerurkar, V. R., & Wang, W. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04081-22 · Cited by 4
Anti-SARS-CoV-2 (COVID-19) vaccination efficacy in patients with severe neuromuscular diseases
Damour, A., Delalande, P., Cordelières, F. P., Lafon, M., Faure, M., Ségovia-Kueny, S., Stalens, C., Mathis, S., Spinazzi, M., Violleau, M., et al. (2023) · Revue Neurologique · doi:10.1016/j.neurol.2023.04.003 · Cited by 4
Vicente-Valor, J., Rodríguez, C., Ferris, M., Chamorro‐de‐Vega, E., Romero-Jiménez, R. M., Costas, D. G., BERMEJO, S. H., Tejerina, F., Osorio‐Prendes, S., Royuela, G. O., et al. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00519-8 · Cited by 4
Hollstein, M. M., Dierks, S., Schön, M. P., Bergmann, A., Abratis, A., Eidizadeh, A., Kaltenbach, S., Schanz, J., Groß, U., Leha, A., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29122 · Cited by 4
Population-based study of the durability of humoral immunity after SARS-CoV-2 infection
Peterhoff, D., Wiegrebe, S., Einhauser, S., Patt, A. J., Beileke, S., Günther, F., Steininger, P. A., Niller, H. H., Burkhardt, R., Küchenhoff, H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1242536 · Cited by 4
Kulkarni, P. S., Padmapriyadarshini, C., Vekemans, J., Bavdekar, A., Gupta, M., Kulkarni, P., Garg, B., Gogtay, N., Tambe, M., Lalwani, S. K., et al. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2304974 · Cited by 4
Self-citationder Heyden, J. V., Leclercq, V., Duysburgh, E., Cornelissen, L., Desombere, I., Roukaerts, I. D. M., & Gisle, L. (2024) · Archives of Public Health · doi:10.1186/s13690-024-01298-1 · Cited by 4
Huo, H., Wang, J., Li, C., Xiao, S., Wang, H., Ge, J., Zhong, G., Wen, Z., Wang, C., Lang, Q., et al. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1468775 · Cited by 4
Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults
Lee, J. H., Shin, Y., Shin, K.-S., Park, J. Y., Kim, M. S., Park, Y.-S., Kim, W., Song, J. Y., Noh, J. Y., Cheong, H. J., et al. (2024) · mSphere · doi:10.1128/msphere.00998-24 · Cited by 4
Determinants of antibody levels and protection against omicron BQ.1/XBB breakthrough infection
Pérez, C. M., Ramírez‐Morros, A., Jiménez, A., Vidal, M., Pradenas, E., Barrios, D., Canyelles, M., Rubio, R., Cuamba, I., Izquierdo, L., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00943-2 · Cited by 4
Madanat, L., Sager, M., O’Connor, D., Thapa, B., Aggarwal, N., Ghimire, B., Lauter, C. B., Maine, G. N., Sims, M. D., & Halalau, A. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s370080 · Cited by 4
Turabián, J. L. (2022) · Archives of Pharmacology and Therapeutics · doi:10.33696/pharmacol.4.031 · Cited by 4
Angkasekwinai, N., Prawjaeng, J., Leelahavarong, P., Khuntha, S., Pheerapanyawaranun, C., Chitpim, N., Srinonprasert, V., & Chokephaibulkit, K. (2022) · Asian Pacific Journal of Allergy and Immunology · doi:10.12932/ap-121122-1501 · Cited by 4
Fernandes, E. R., Taminato, M., Apostólico, J. D. S., Gabrielonni, M. C., Lunardelli, V. A. S., Maricato, J. T., Andersen, M. L., Tufik, S., & Rosa, D. S. (2023) · Journal of Allergy and Clinical Immunology Global · doi:10.1016/j.jacig.2023.100083 · Cited by 5
Moal, V., Valade, M., Boschi, C., Robert, T., Orain, N., Bancod, A., Edouard, S., Colson, P., & Scola, B. L. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1147455 · Cited by 4
Oliosi, E., Flahault, A., Charre, C., Veyer, D. L., Combier, A., Lafont, E., Karras, A., Mouthon, L., Avouac, J., Terrier, B., et al. (2023) · Clinical Rheumatology · doi:10.1007/s10067-023-06638-0 · Cited by 4
Basto-Abreu, A. C., Carnalla, M., Torres‐Ibarra, L., Sánchez‐Pájaro, A., Martínez, M. R., Martínez-Barnetche, J., López-Martı́nez, I., Aparicio‐Antonio, R., Shamah‐Levy, T., Alpuche-Aranda, C. M., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29038 · Cited by 4
Wagatsuma, K., Saito, R., Yoshioka, S., Yamazaki, S., Sato, R., Iwaya, M., Takahashi, Y., Chon, I., Naito, M., & Watanabe, H. (2023) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2023.09.021 · Cited by 4
The Antibodies’ Response to SARS-CoV-2 Vaccination: 1-Year Follow Up
Nicolai, E., Tomassetti, F., Pelagalli, M., Sarubbi, S., Minieri, M., Nisini, A., Nuccetelli, M., Ciotti, M., Pieri, M., & Bernardini, S. (2023) · Biomedicines · doi:10.3390/biomedicines11102661 · Cited by 4
Roessler, J., Pich, D., Krähling, V., Becker, S., Keppler, O. T., Zeidler, R., & Hammerschmidt, W. (2023) · Biomedicines · doi:10.3390/biomedicines11112892 · Cited by 4
Griessbach, A., Chammartin, F., Abela, I. A., Amico, P., Stoeckle, M. P., Eichenberger, A. L., Hasse, B. K., Braun, D. L., Schuurmans, M. M., Müller, T. F., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad536 · Cited by 4
Safitri, I. A., Sugijo, Y., Puspasari, F., Masduki, F. F., Ihsanawati, I., Giri-Rachman, E. A., Artarini, A., Tan, M. I., & Natalia, D. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100443 · Cited by 4
Richier, Q., Valence, B. D., Chopin, D., Gras, E., Levi, L. I., Aad, Y. A., Pacanowski, J., Meynard, J., Plaçais, L., Fey, D., et al. (2024) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.13272 · Cited by 4
Huygens, S., Preijers, T., Swaneveld, F. H., Budde, I. K., GeurtsvanKessel, C. H., Koch, B. C. P., & Rijnders, B. J. A. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01351-w · Cited by 4
Augello, M., Wagenhäuser, I., Krone, M., Dauby, N., Ferrara, P., Sabbatucci, M., Ruță, S. M., Rezahosseini, O., Velikov, P., Gkrania‐Klotsas, E., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126184 · Cited by 4
Self-citationSARS-CoV-2 Vaccine-Induced Humoral Immunity in Immunocompetent European Adults: A Systematic Review
Bylica, I., Jachowicz-Matczak, E., Brodowicz, J., Sułkowska, J., Bociąga‐Jasik, M., Heczko, P. B., Gagatek, S. G., Bylica, J., & Wójkowska‐Mach, J. (2025) · Microorganisms · doi:10.3390/microorganisms13030535 · Cited by 4
Tajuelo, A., Carretero, O., García‐Ríos, E., López‐Siles, M., Cano, O., Vázquez, M., Más, V., Rodríguez‐Góncer, I., Lalueza, A., López‐Medrano, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878812 · Cited by 4
Puthanakit, T., Nantanee, R., Jaru-Ampornpan, P., Chantasrisawad, N., Sophonphan, J., Meepuksom, T., Jupimai, T., Sodsai, P., Anugulruengkitt, S., & Hirankarn, N. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100211 · Cited by 4
Nham, E., Hyun, H., Seong, H., Yoon, J. G., Noh, J. Y., Song, J. Y., Kim, W. J., & Cheong, H. J. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0074 · Cited by 4
Choi, M. J., Heo, J. Y., Seo, Y. B., Yoon, Y. K., Sohn, J. W., Noh, J. Y., Cheong, H. J., Kim, W. J., Choi, J., Lee, Y. J., et al. (2023) · Vaccines · doi:10.3390/vaccines11010120 · Cited by 4
Williams, E., Kizhner, A., Stark, V. S., Nawab, A., Muniz, D. D., Tribin, F. E., Carreño, J. M., Bielak, D. A., Singh, G., Hoffer, M. E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.971277 · Cited by 4
Passenberg, M., Authorsen-Grudmann, R., Frey, A., Korth, J., Zmudzinski, J., Anastasiou, O. E., Möhlendick, B., Schmidt, H., Rashidi‐Alavijeh, J., & Willuweit, K. (2023) · Vaccines · doi:10.3390/vaccines11030572 · Cited by 4
Berry, C., Pavot, V., Anosova, N. G., Kishko, M., Li, L., Tibbitts, T., Raillard, A., Gautheron, S., Cummings, S., Bangari, D. S., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00302-z · Cited by 4
VACCINES VERSUS COVID-19 VACCINES: MANEUVER TIMELINE OF DEVELOPMENT AND TRIAL DESIGNS
Gaddam, S., Pasupulati, H., & Padi, S. S. V. (2023) · World Journal of Current Medical and Pharmaceutical Research · doi:10.37022/wjcmpr.v5i3.265 · Cited by 4
Muslimah, A. H., Tiara, M. R., Djauhari, H., Dewantara, M. H. A., Susandi, E., Indrati, A. R., Alisjahbana, B., Soeroto, A. Y., & Wisaksana, R. (2023) · Vaccines · doi:10.3390/vaccines11081300 · Cited by 4
Leys, Y. E., Nwokocha, M., Walker, J. P., Butterfield, T. R., Frater, V., Thompson, T. K., Anderson, M., Cloherty, G., & Anzinger, J. J. (2022) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-1128 · Cited by 5
Dimitrov, Y., Krummel, T., Chantrel, F., Faller, A.-L., Ott, J., David, D., Bazin-Kara, D., Hannedouche, T. P., & Borni-Duval, C. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac082 · Cited by 4
Ambrosi, P., Basire, A., & Habib, G. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13945 · Cited by 4
Immunogenicity of heterologous prime/boost inactivated and mRNA COVID-19 vaccinePreprint
Wanlapakorn, N., Yorsaeng, R., Phowatthanasathian, H., Suntronwong, N., Kanokudom, S., Sudhinaraset, N., & Poovorawan, Y. (2021) · medRxiv · doi:10.1101/2021.11.20.21266644 · Cited by 4
Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role?
Broccolo, F. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-1345 · Cited by 4
Moore, S. C., Kronsteiner, B., Longet, S., Adele, S., Deeks, A. S., Liu, C., Dejnirattisai, W., Silva-Reyes, L., Meardon, N., Faustini, S. E., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4180810 · Cited by 5
Self-citationHickey, T. E., Mudunuri, U. S., Hempel, H., Kemp, T. J., Roche, N., Talsania, K., Sellers, B. A., Cherry, J. M., & Pinto, L. A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1502458 · Cited by 3
Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV
Augello, M., Bono, V., Rovito, R., Tavelli, A., Santoro, A., Tincati, C., Vergori, A., Azzini, A. M., Righi, E., Spiteri, G., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-00799-6 · Cited by 3
Diemert, D. J., Graciaa, D. S., Zhang, B., Rouphael, N., Branche, A. R., Martin, T., Jackson, L. A., Presti, R. M., Kamidani, S., Mahgoub, S. M., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127718 · Cited by 3
Walmsley, S. L., Nabipoor, M., Chao, G. Y. C., Lovblom, L. E., Ward, L. A., Ravindran, R., Colwill, K., Gingras, A., & Gommerman, J. L. (2025) · ImmunoHorizons · doi:10.1093/immhor/vlaf068 · Cited by 3
Estimation of undetected asymptomatic infections of COVID-19: a mathematical modeling approach
Choi, Y., Kim, P., & Lee, C. H. (2025) · Scientific Reports · doi:10.1038/s41598-025-28374-y · Cited by 3
Polypore mushroom mycelia as an adjunct to COVID-19 vaccination: a randomized clinical trial
Saxe, G. A., Smith, C. N., Golshan, S., Shekhtman, T., Bair, Z. J., Beathard, C., Davis, R. A., MacElhern, L., Shubov, A., Slater, D. W., et al. (2026) · BMC Immunology · doi:10.1186/s12865-026-00809-9 · Cited by 3
Wang, X., Deng, Y. L., Zhao, L., Wang, L., Fu, Z., Tang, L., Ye, F., Liu, Q., Wang, W., Wang, S., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.037 · Cited by 3
Mingyao, B., Tam, A. R., Chan, K. W., Hung, I. F., Tang, S. C. W., Chan, T. M., & Yap, D. Y. H. (2024) · Kidney Diseases · doi:10.1159/000536308 · Cited by 3
The Long-Term Immunogenicity of mRNABNT162b Third Vaccine Dose in Solid Organ Transplant Recipients
Zingaropoli, M. A., Guardiani, M., Dominelli, F., Tortellini, E., Garofalo, M., Dezza, F. C., Centofanti, A., Carillo, C., Napoli, A., Venuta, F., et al. (2024) · Vaccines · doi:10.3390/vaccines12030224 · Cited by 3
Bertrand, D., Laurent, C., Lemoine, M., Lebourg, L., Hanoy, M., Roy, F. L., Nezam, D., Pruteanu, D., Grangé, S., de Nattes, T., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12040722 · Cited by 3
Borgogna, C., Ferrante, D., Rosso, G., Guglielmetti, G., Cigno, I. L., Raviola, S., Caneparo, V., Quaglia, M., Cantaluppi, V., & Gariglio, M. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29710 · Cited by 3
Chen, X., Meng, X., Wu, Q., Lim, W. W., Xin, Q., Cowling, B. J., Meng, W., Yu, H., & Covas, D. T. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106315 · Cited by 3
Morgan, G., Fung, C. Y. J., Gingras, A., Colwill, K., Briollais, L., Frangione, E., Wolday, D., Qi, F., Pasculescu, A., Delgado-Brand, M., et al. (2024) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2024.110859 · Cited by 3
Alhasan, K. A., Raina, R., Boyer, O., Koh, L. J., Felix, M. B., Sethi, S. K., Amer, Y. S., Coccia, P. A., Temsah, M.-H. A., Exantus, J., et al. (2024) · Pediatric Nephrology · doi:10.1007/s00467-024-06565-5 · Cited by 3
Lürken, K., Meinecke, A., Manthey, L. A., Cossmann, A., Stankov, M. V., Klawonn, F., Scharff, A. Z., Steffens, S., Dopfer‐Jablonka, A., Müller, F., et al. (2025) · European journal of medical research · doi:10.1186/s40001-025-02274-3 · Cited by 3
Laurent, P., Renou, M., Esper, N. E., Choukroun, G. J., Pommerolle, P., Laburthe, S., & Caillard, P. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04264-3 · Cited by 3
Mkhize, N. N., Zhang, B., Brackett, C., Elyanu, P., Tapley, A., Dadabhai, S. S., Hu, J., Do, B. T. N., Schuster, D. J., Heptinstall, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63948-4 · Cited by 3
Drapkina, O. M., Berns, S. A., Gorshkov, A. Y., Ryzhakova, L. N., Иванова, А. А., Emelyanov, A. V., Voinova, S. N., Karateev, R. A., Arablinsky, N. A., Rodionova, A. A., et al. (2022) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3295 · Cited by 3
Mixed outcomes following a third SARS-CoV-2 vaccine dose in previously unresponsive people with HIV
Hassold, N., Brichler, S., Gater, Y., Leclerc, D., Gordien, E., Bouchaud, O., Carbonnelle, É., Mechai, F., Cordel, H., & Delagreverie, H. M. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105347 · Cited by 3
Population-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil
Paula, N. M., Conzentino, M. S., Gonçalves, A. C. A., da Silva, R., Weissheimer, K. V., Kluge, C. H. S., Marins, P. H. S. A., Camargo, H. S. C., Farias, L. R. P., Sant’Ana, T. P., et al. (2022) · Vaccines · doi:10.3390/vaccines11010021 · Cited by 4
Breu, M., Lechner, C., Schneider, L., Tobudic, S., Winkler, S., Siegert, S., Baumann, M., Seidl, R., Berger, T., & Kornek, B. (2023) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2023.02.017 · Cited by 3
Immune response to BNT162b2 SARS-CoV-2 vaccine in patients living with HIV: The COVIH-DAPT study
Manni, S., Ruetsch-Chelli, C., Fabre, R., Ticchioni, M., Graça, D., Pradier, C., Seitz‐Polski, B., Lotte, L., Brglez, V., & Vassallo, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1136723 · Cited by 3
Habermann, E., Frommert, L. M., Ghannam, K., My, L. N., Gieselmann, L., Tober‐Lau, P., Klotsche, J., de Silva, A. N. A., ten Hagen, A., Zernicke, J., et al. (2023) · Journal of Clinical Virology · doi:10.1016/j.jcv.2023.105518 · Cited by 3
Monin, M. B., Gorny, J. G., Berger, M., Baier, L. I., Zhou, T., Mahn, R., Sadeghlar, F., Möhring, C., Boesecke, C., van Bremen, K., et al. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-1065 · Cited by 3
Triebelhorn, J., Schneider, J., Spinner, C. D., Iakoubov, R., Voit, F., Wagner, L., Erber, J., Rothe, K., Berthele, A., Pernpeintner, V., et al. (2024) · Infection · doi:10.1007/s15010-023-02171-z · Cited by 3
Zhang, X., Guan, L., Li, N., Wang, Y., Li, L., Liu, M., He, Q., Lu, J., Zeng, H., Yu, S., et al. (2024) · Viruses · doi:10.3390/v16040554 · Cited by 3
Costiniuk, C. T., Lee, T., Singer, J., Galipeau, Y., Arnold, C. R., Langlois, M., Needham, J., Jenabian, M.-A., Burchell, A. N., Samji, H., et al. (2024) · Vaccines · doi:10.3390/vaccines12050447 · Cited by 3
Lapadula, G., Mezzadri, L., Cascio, G. L., Antolini, L., Malandrin, S. M. I., Ranzani, A., Limonta, S., Cavallero, A., & Bonfanti, P. (2024) · Infection · doi:10.1007/s15010-024-02250-9 · Cited by 3
Antibody Titers and the Risk of Infection During the SARS-CoV-2 Omicron Phase in Bizen City, Japan
Kadowaki, T., Sasaki, A., Matsumoto, N., Mitsuhashi, T., Hagiya, H., Takao, S., & Yorifuji, T. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae207 · Cited by 6
Tahsin, A., Bhattacharjee, P., Saba, A. A., Yasmin, T., & Nabi, A. N. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126157 · Cited by 3
Константиновна, П. С., Kozlovskaya, L. I., Анатольевич, Е. А., Sirazova, D. I., Shustova, E. Y., Артамонова, Е. А., Siniugina, A. A., Gordeychuk, I. V., Troshyanskiy, D. V., Kosareva, E. V., et al. (2024) · Epidemiology and Vaccinal Prevention · doi:10.31631/2073-3046-2024-23-5-63-72 · Cited by 3
Marc, G. P., Coria, L. M., Ceballos, A., Rodriguez, J. M., Lombardo, M., Bruno, L. A., Córdoba, F. P., Cassero, C. G. F., Salvatori, M., Medrano, M. R., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127045 · Cited by 3
Turabián, J. L. (2022) · Journal of SARS-CoV-2 Research · doi:10.36013/sarc-cov-2.v2i.85 · Cited by 3
Kaira, A. N., Murzina, A. A., Свитич, О. А., & Kal’nin, I. B. (2022) · Sanitarnyj vrač (Sanitary Doctor) · doi:10.33920/med-08-2207-01 · Cited by 3
Masset, C., Garandeau, C., Houzet, A., Kervella, D., Ville, S., Cantarovich, D., Clech, A. L., Leman, C., Gaisne, R., Guillot-Gueguen, C., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.10.002 · Cited by 3
Krifors, A., Freyhult, E., Teljebäck, M. R., Wallin, R. P. A., Winqvist, O., & Månsson, E. (2022) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2022.2142662 · Cited by 3
Performance of an interferon-γ release assay-based test for cell-mediated immunity to SARS-CoV-2
Brito, L. F., Tödter, S., Kottlau, J., Cermann, K., Spier, A., Petersen, E. L., Schäfer, I., Twerenbold, R., Aepfelbacher, M., Lütgehetmann, M., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1069968 · Cited by 3
Campbell, E., Dobkin, J., Osorio, L., Kolloli, A., Ramasamy, S., Kumar, R., Sant’Angelo, D. B., Subbian, S., Denzin, L. K., & Anderson, S. (2023) · Vaccines · doi:10.3390/vaccines11040832 · Cited by 3
Farnsworth, C. W., O’Neil, C. A., Dalton, C., McDonald, D., Vogt, L. C., Hock, K. G., Arter, O. G., Wallace, M. A., Muenks, C. E., Amor, M., et al. (2023) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfad042 · Cited by 3
Garcia-Cirera, S., Calvet, J., Delgado, J. F., Berenguer, A., Orellana, C., Rusiñol, M., Llop-Vilaltella, M., Arévalo, M., Garcia-Pinilla, A., Costa, E., et al. (2024) · European journal of medical research · doi:10.1186/s40001-023-01620-7 · Cited by 3
Tai, C. G.-L., Haviland, M. J., Kissler, S. M., Lucia, R. M., MERSON, M. H., Maragakis, L. L., Ho, D. D., Anderson, D. J., DiFiori, J. P., Grubaugh, N. D., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29505 · Cited by 3
Association between antibody responses post-vaccination and severe COVID-19 outcomes in Scotland
Macdonald, C., Palmateer, N. E., McAuley, A., Lindsay, L., Hasan, T., Hameed, S. S., Hall, E., Jeffrey, K., Grange, Z., Gousias, P., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00898-w · Cited by 3
Qi, Y., Zheng, H., Wang, J., Chen, Y., Guo, X., Li, Z., Zhang, W., Zhou, J., Wang, S., Lin, B., et al. (2024) · Vaccines · doi:10.3390/vaccines12070781 · Cited by 3
Placebo control group in COVID-19 vaccine trials: context and timing matters
Dal‐Ré, R. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03259-x · Cited by 3
Shibata, H., Nishimura, K., Maeda, T., Honma, M., Goda, Y., Ishii‐Watabe, A., & Saito, Y. (2022) · Bioanalysis · doi:10.4155/bio-2021-0254 · Cited by 3
Metadata
- Authors
- Feng, S., Phillips, D. J., White, T., Sayal, H., Aley, P. K., Bibi, S., Dold, C., Fuskova, M., Gilbert, S. C., Hirsch, I., Humphries, H. E., Jepson, B., Kelly, E. J., Plested, E., Shoemaker, K., Thomas, K. M., Vekemans, J., Villafana, T. L., Lambe, T., Pollard, A. J., Voysey, M., the Oxford COVID Vaccine Trial Group, Adlou, S., Allen, L., Angus, B., Anslow, R., Asselin, M.-C., Baker, N., Baker, P., Barlow, T., Beveridge, A., Bewley, K. R., Brown, P., Brunt, E., Buttigieg, K. R., Camara, S., Charlton, S., Chiplin, E., Cicconi, P., Clutterbuck, E. A., Collins, A. M., Coombes, N. S., Clemens, S. A. C., Davison, M., Demissie, T., Dinesh, T., Douglas, A. D., Duncan, C. J. A., Emary, K. R. W., Ewer, K. J., Felle, S., Ferreira, D. M., Finn, A., Folegatti, P. M., Fothergill, R., Fraser, S., Garlant, H., Gatcombe, L., Godwin, K. J., Goodman, A. L., Green, C. A., Hallis, B., Hart, T. C., Heath, P. T., Hill, H., Hill, A. V. S., Jenkin, D., Kasanyinga, M., Kerridge, S., Knight, C., Leung, S., Libri, V., Lillie, P. J., Marinou, S., McGlashan, J., McGregor, A. C., McInroy, L., Minassian, A. M., Mujadidi, Y. F., Penn, E. J., Petropoulos, C. J., Pollock, K. M., Proud, P. C., Provstgaard-Morys, S., Rajapaska, D., Ramasamy, M. N., Sanders, K., Shaik, I., Singh, N., Smith, A., Snape, M. D., Song, R., Shrestha, S., Sutherland, R. K., Thomson, E. C., Turner, D. P. J., Webb-Bridges, A., Wrin, T., & Williams, C. J.
- Affiliations
- University of Oxford (GB)
- AstraZeneca (United Kingdom) (GB)
- Public Health England (GB)
- AstraZeneca (United States) (US)
- AstraZeneca (Sweden) (SE)
- Liverpool School of Tropical Medicine (GB)
- University of Siena (IT)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- University of Bristol (GB)
- St Thomas' Hospital (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- St George's, University of London (GB)
- University of Hull (GB)
- London North West Healthcare NHS Trust (GB)
- LabCorp (United States) (US)
- NHS Lothian (GB)
- Nottingham University Hospitals NHS Trust (GB)
- Aneurin Bevan University Health Board (GB)
- Corresponding author
- Voysey, Merryn
- ORCID
- Feng, Shuo
- Phillips, Daniel J.
- Aley, Parvinder K.
- Bibi, Sagida
- Dold, Christina
- Fuskova, Michelle
- Gilbert, Sarah C.
- Hirsch, Ian
- Humphries, Holly E.
- Jepson, Brett
- Kelly, Elizabeth J.
- Plested, Emma
- Thomas, Kelly M.
- Vekemans, Johan
- Villafana, Tonya L.
- Lambe, Teresa
- Pollard, Andrew J.
- Voysey, Merryn
- Allen, Lauren
- Angus, Brian
- Anslow, Rachel
- Asselin, Marie-Claude
- Baker, Natalie
- Baker, Philip
- Bewley, Kevin R.
- Brown, Phillip
- Buttigieg, Karen R.
- Camara, Susana
- Charlton, Sue
- Cicconi, Paola
- Clutterbuck, Elizabeth A.
- Collins, Andrea M.
- Coombes, Naomi S.
- Clemens, Sue Ann Costa
- Douglas, Alexander D.
- Duncan, Christopher J. A.
- Emary, Katherine R. W.
- Ewer, Katie J.
- Felle, Sally
- Ferreira, Daniela M.
- Finn, Adam
- Folegatti, Pedro M.
- Garlant, Harriet
- Goodman, Anna L.
- Green, Christopher A.
- Hallis, Bassam
- Hart, Thomas C.
- Heath, Paul T.
- Hill, Helen
- Hill, Adrian V. S.
- Jenkin, Daniel
- Kasanyinga, Mwila
- Kerridge, Simon
- Leung, Stephanie
- Libri, Vincenzo
- Lillie, Patrick J.
- Marinou, Spyridoula
- McGregor, Alastair C.
- Minassian, Angela M.
- Mujadidi, Yama F.
- Petropoulos, Christos J.
- Pollock, Katrina M.
- Proud, Pamela C.
- Provstgaard-Morys, Samuel
- Ramasamy, Maheshi N.
- Sanders, Katherine
- Smith, Andrew
- Snape, Matthew D.
- Song, Rinn
- Sutherland, Rebecca K.
- Thomson, Emma C.
- Turner, David P. J.
- Williams, Christopher J.
- Venue
- Nature Medicine
- Published
- 2021-09-29
- Volume
- 27
- Issue
- 11
- Pages
- 2032-2040
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC8604724
- OpenAlex
- W3174017401
- Cited by
- 1,163
- References
- 41
- Citations by year
- 2026: 36 · 2025: 94 · 2024: 155 · 2023: 255 · 2022: 515 · 2021: 106
- FWCI
- 81.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Nature Medicine (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (publishedVersion, cc-by)
- St George's Online Research Archive (St George's University of London) (acceptedVersion)
- LSTM Online Archive (Liverpool School of Tropical Medicine) (acceptedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Liverpool John Moores University (acceptedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Funders
- DH | National Institute for Health Research (NA)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, binding antibodies, neutralizing antibodies, anti-spike antibodies, anti-RBD antibodies, pseudovirus neutralization, symptomatic infection, asymptomatic infection, Alpha variant, vaccine correlates of protection, vaccine licensure
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Viral, Female, United Kingdom, Humans, Immunization, Secondary, Male, Middle Aged, Vaccination, Cohort Studies, Treatment Outcome, Infection Control, Young Adult, Immunity, Humoral, Antibodies, Neutralizing, Asymptomatic Infections, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
